BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 6.1%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price rose 6.1% during trading on Friday . The stock traded as high as $3.64 and last traded at $3.64. Approximately 6,961,500 shares traded hands during mid-day trading, a decline of 9% from the average daily volume of 7,646,306 shares. The stock had previously closed at $3.43.

BCRX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, August 7th. ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. BidaskClub downgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 25th. BTIG Research initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 16th. They

Read More

Continue Reading

ROSEN, LEADING INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Teva Pharmaceuticals Industries Li

 ROSEN, LEADING INVESTOR COUNSEL, Announces Filing of Securities Class Action
Lawsuit Against Teva Pharmaceuticals Industries Limited; Encourages Investors
          with Losses in Excess of $100K to Contact the Firm - TEVA

PR Newswire

NEW YORK, Sept. 25, 2020

NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor
rights law firm, announces the filing of a class action lawsuit on behalf of
purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE:
TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class
Period"). The lawsuit seeks to recover damages for Teva investors under the
federal securities laws.

Rosen Law Firm, P.A. Logo

To join the Teva class action, go to
http://www.rosenlegal.com/cases-register-1956.html or call Phillip Kim, Esq.
toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com
for information on the class action.

The complaint alleges that throughout the Class Period, Defendants made
materially false and misleading statements regarding 
Read More

Continue Reading

Genetron Health and CStone Pharmaceuticals Announce Launch of Clinical Trial in China for Companion Diagnostic Test in

Genetron Health and CStone Pharmaceuticals Announce Launch of Clinical Trial
in China for Companion Diagnostic Test in Development for Avapritinib

BEIJING and SUZHOU, China, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Genetron
Holdings Limited (“Genetron Health”, Nasdaq: GTH), a leading precision
oncology platform company in China that specializes in offering molecular
profiling tests, early cancer screening products and companion diagnostics
development, and its strategic partner CStone Pharmaceuticals (“CStone”, HKEX:
2616) today announced the launch of a multi-center clinical trial in China for
the joint development of a companion diagnostic (CDx) test for avapritinib.
This represents a key milestone in the companies’ collaboration. Avapritinib
is a kinase inhibitor discovered by CStone’s partner Blueprint Medicines.

Genetron Health and CStone are jointly developing a CDx kit to detect the
D842V mutation in the human platelet-derived growth factor receptor alpha
(PDGFRA) gene using a polymerase chain reaction (PCR)-based method. The CDx
test kit utilizes a 
Read More

Continue Reading

Arena Pharmaceuticals (NASDAQ:ARNA) Upgraded by BidaskClub to “Buy”

BidaskClub upgraded shares of Arena Pharmaceuticals (NASDAQ:ARNA) from a hold rating to a buy rating in a research note released on Friday, BidAskClub reports.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. began coverage on shares of Arena Pharmaceuticals in a research note on Monday, September 14th. They issued an overweight rating on the stock. Citigroup increased their target price on Arena Pharmaceuticals from $83.00 to $120.00 and gave the company a buy rating in a research note on Friday, September 18th. Needham & Company LLC restated a buy rating and issued a $70.00 price objective on shares of Arena Pharmaceuticals in a research note on Thursday, August 6th. Wells Fargo & Company raised their price target on shares of Arena Pharmaceuticals from $60.00 to $78.00 and gave the stock an overweight rating in a research report on Thursday, August 6th. Finally, Guggenheim upped

Read More

Continue Reading

Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Hold at BidaskClub

BidaskClub upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a sell rating to a hold rating in a research report sent to investors on Friday morning, BidAskClub reports.

Several other equities analysts have also recently commented on the stock. BMO Capital Markets boosted their target price on shares of Alnylam Pharmaceuticals from $173.00 to $196.00 and gave the company an outperform rating in a research report on Monday, July 20th. SVB Leerink boosted their price objective on shares of Alnylam Pharmaceuticals from $89.00 to $90.00 and gave the company a market perform rating in a research report on Friday, August 7th. Oppenheimer downgraded Alnylam Pharmaceuticals from an outperform rating to a market perform rating and reduced their target price for the company from $162.00 to $156.00 in a report on Tuesday, August 11th. They noted that the move was a valuation call. ValuEngine raised Alnylam Pharmaceuticals from a hold rating to

Read More

Continue Reading

AQR Capital Management LLC Reduces Holdings in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

AQR Capital Management LLC decreased its position in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 10.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,533 shares of the biopharmaceutical company’s stock after selling 3,839 shares during the quarter. AQR Capital Management LLC owned approximately 0.05% of Arena Pharmaceuticals worth $1,985,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of ARNA. UBS Group AG grew its holdings in shares of Arena Pharmaceuticals by 40.9% during the first quarter. UBS Group AG now owns 36,182 shares of the biopharmaceutical company’s stock worth $1,520,000 after purchasing an additional 10,496 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Arena Pharmaceuticals by 2.0% during the first quarter. Rhumbline Advisers now owns 76,488 shares of the biopharmaceutical company’s stock

Read More

Continue Reading

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Shares Acquired by California Public Employees Retirement System

California Public Employees Retirement System raised its holdings in shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 203.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 100,400 shares of the biotechnology company’s stock after acquiring an additional 67,300 shares during the period. California Public Employees Retirement System owned approximately 0.19% of Pieris Pharmaceuticals worth $311,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Corriente Advisors LLC acquired a new position in shares of Pieris Pharmaceuticals in the 1st quarter valued at $4,063,000. Candriam Luxembourg S.C.A. lifted its stake in shares of Pieris Pharmaceuticals by 57.6% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 2,345,468 shares of the biotechnology company’s stock valued at $7,271,000 after purchasing an additional 857,293

Read More

Continue Reading

Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about edasalonexent, in Phase 3 development for the treatment of Duchenne muscular dystrophy, at the following virtual investor conferences this month:

  • HC Wainwright 22nd Annual Global Investment Conference on Monday, September 14th, at 4:00pm EDT
  • Cantor Virtual Healthcare Conference on Wednesday, September 16th, at 3:20pm EDT

Catabasis will also be participating in the Oppenheimer Virtual Fall Healthcare, Life Sciences, & MedTech Summit, which will take place from September 21st – 23rd, 2020.

Live webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will also be available for 30 days following the event.

About Edasalonexent (CAT-1004)

Edasalonexent (CAT-1004) is an investigational oral small molecule designed to inhibit NF-kB that is

Read More

Continue Reading

Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness

Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes,
Reduce Outstanding Indebtedness

Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter
2020

THE  WOODLANDS,   Texas,  Sept.   23,  2020   (GLOBE  NEWSWIRE)   --   Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered  into
separate, privately-negotiated exchange agreements with certain holders of its
5.25% Convertible Senior Notes due 2021  under which such holders have  agreed
to exchange  an aggregate  principal  amount of  $62.55  million of  Notes  in
exchange for  aggregate consideration  consisting of  $41.03 million  in  cash
(including  $1.07  million  of  accrued  interest)  and  8,746,117  shares  of
Lexicon’s common stock, par value $0.001 per share.

The transactions  are expected  to close  by September  28, 2020,  subject  to
customary closing  conditions.  Immediately  following  the  closings,  $24.95
million in aggregate principal amount of the Notes will remain outstanding.

The completion of  the transactions will  reduce Lexicon’s remaining  interest
expense through 2021  
Read More

Continue Reading

Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase

  Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as
  Part of Existing $160 Million Share Repurchase Program

Business Wire

WOODCLIFF LAKE, N.J. -- September 24, 2020

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today
announced that its Board of Directors has approved a $25 million accelerated
share repurchase (“ASR”) transaction with JPMorgan Chase Bank, National
Association (“JP Morgan”) as part of the Company’s existing $160 million share
repurchase program.

The specific number of shares to be repurchased pursuant to the ASR is based
on the average of the daily volume weighted average share prices of the
Company’s common stock, less a discount, during the term of the ASR program.
Based on yesterday’s closing price, the $25 million ASR would represent
approximately 5% of the Company’s basic outstanding shares. Upon completion of
the ASR, Eagle will have bought back a total of approximately $205 million of
its stock since 
Read More

Continue Reading

Load More